Compare iShares Core High Dividend ETF (HDV) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs McKesson Corporation — how do they compare? iShares Core High Dividend ETF trades at $28.16, while McKesson Corporation trades at $829.3 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| HDV | MCK | |
|---|---|---|
52-Week High | $28.36 | $995.69 |
52-Week Low | $23.64 | $659.01 |
Market Cap | — | $97.35B |
Sector | — | Health |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.18, down 0.25% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a 3.0% dividend yield, with recent payouts of $0.19 and $0.09 per share. News coverage highlights HDV's defensive sector focus and competitive expense ratio compared to peers like SCHD and VYM, though some analysts note concentration risk in energy holdings.
Outlook remains cautiously positive given HDV's low volatility and income appeal, but investors face risks from oil price sensitivity and modest dividend growth. The ETF's quality screen provides stability, yet sector concentration may limit upside if energy underperforms.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
